Asapiprant - BioAge Labs
Alternative Names: BGE-175; S-555739Latest Information Update: 28 Sep 2024
At a glance
- Originator Shionogi
- Developer BioAge Labs; Shionogi
- Class Acetic acids; Antiallergics; Antivirals; Oxazoles; Piperazines; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Discontinued Allergic rhinitis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (PO)
- 21 Mar 2022 Pharmacodynamics data from preclinical studies in COVID-2019 infections released by BioAge Labs
- 18 Mar 2021 Phase-II clinical trials in COVID-2019 infections in Argentina, Brazil (PO) (NCT04705597)